American Society of Anesthesia class I and II patients scheduled for surgery under general anesthesia
Conditions
Sponsors
University Hospital Ghent
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: American Society of Anesthesia class I and II patients, aged 18-60 years, scheduled for surgery under general anesthesia Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: weight less than 70% or more than 130% of ideal body weight, neurological disorder, diseases involving the cardiovascular system (hypertension, coronary artery disease, prior AMI, any valvular and/or muscular disease involving decrease of the ejection fraction, arrhythmias, which are either symptomatic or require continuous medication/pacemaker/AICD), pulmonary disease including asthma, severe COPD…., Gastric diseases including reflux, endocrinological diseases, and recent use of psycho-active medication, including alcohol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the pharmacodynamic interaction between sevoflurane and remifentanil. The pharmacodynamic clinical effects that will be studied are EEG depression and arousal reactions in response to different clinically relevant stimuli. ;Secondary Objective: ;Primary end point(s): EEG depression and arousal reactions in response to different clinically relevant stimuli. | — |
Countries
Belgium
Outcome results
None listed